Cargando…
Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
BACKGROUND: Acute graft versus host disease (aGVHD) remains a leading cause of transplant-related mortality following allogeneic haematopoietic cell transplantation (allo-HCT). Human amniotic mesenchymal stem cells (hAMSCs) are a novel mesenchymal stem cells (MSCs), which have stronger proliferation...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378934/ https://www.ncbi.nlm.nih.gov/pubmed/34429630 http://dx.doi.org/10.2147/JIR.S323054 |
_version_ | 1783740903983153152 |
---|---|
author | Gao, Ya Li, Weiru Bu, Xiaoyin Xu, Ying Cai, Shengchun Zhong, Jinman Du, Meixue Sun, Haitao Huang, Liping He, Yongjian Hu, Xiumei Liu, Qifa Jin, Hua Wang, Qian Ping, Baohong |
author_facet | Gao, Ya Li, Weiru Bu, Xiaoyin Xu, Ying Cai, Shengchun Zhong, Jinman Du, Meixue Sun, Haitao Huang, Liping He, Yongjian Hu, Xiumei Liu, Qifa Jin, Hua Wang, Qian Ping, Baohong |
author_sort | Gao, Ya |
collection | PubMed |
description | BACKGROUND: Acute graft versus host disease (aGVHD) remains a leading cause of transplant-related mortality following allogeneic haematopoietic cell transplantation (allo-HCT). Human amniotic mesenchymal stem cells (hAMSCs) are a novel mesenchymal stem cells (MSCs), which have stronger proliferation and immunomodulatory ability compared with bone marrow mesenchymal stem cells (BM-MSCs). Besides, as the amniotic membrane is often treated as medical waste after delivery, hAMSCs can be obtained conveniently and noninvasively. The aim of this study was to explore the therapeutic efficacy and underlying mechanisms of hAMSCs transplantation for the humanized aGVHD mouse model. METHODS: We established a humanized aGVHD mouse model by transplanting human peripheral blood mononuclear cells (PBMCs) into NOD-Prkdc(scid)IL2rγ(null) (NPG) mice, human amniotic membrane collected from discarded placenta of healthy pregnant women after delivery and hAMSCs were extracted from amniotic membrane and expanded in vitro. Mice were divided into untreated group (Control), aGVHD group (aGVHD), and hAMSCs treatment group (aGVHD+hAMSCs), the hAMSCs labeled with GFP were administered to aGVHD mice to explore the homing ability of hAMSCs. T effector and regulatory T cells (Tregs) levels and cytokines of each group in target organs were detected by flow cytometry and cytometric bead array (CBA), respectively. RESULTS: We successfully established a humanized aGVHD mouse model using NPG mice. The hAMSCs have the ability to inhibit aGVHD in this mouse model through reduced villous blunting and lymphocyte infiltration of the gut while reducing inflammatory edema, tissue destruction and lymphocyte infiltration into the parenchyma of the liver and lung. hAMSCs suppressed CD3+CD4+ T and CD3+CD8+ T cell expression and increased the proportion of Tregs, and besides, hAMSCs can reduce the levels of IL-17A, INF-γ, and TNF in aGVHD target organs. CONCLUSION: The NPG murine environment was capable of activating human T cells to produce aGVHD pathology to mimic aGVHD as in humans. The hAMSCs controlled aGVHD by decreasing inflammatory cytokine secretion within target organs by modulating the balance of Tregs and T effector cells in humanized mice. |
format | Online Article Text |
id | pubmed-8378934 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-83789342021-08-23 Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells Gao, Ya Li, Weiru Bu, Xiaoyin Xu, Ying Cai, Shengchun Zhong, Jinman Du, Meixue Sun, Haitao Huang, Liping He, Yongjian Hu, Xiumei Liu, Qifa Jin, Hua Wang, Qian Ping, Baohong J Inflamm Res Original Research BACKGROUND: Acute graft versus host disease (aGVHD) remains a leading cause of transplant-related mortality following allogeneic haematopoietic cell transplantation (allo-HCT). Human amniotic mesenchymal stem cells (hAMSCs) are a novel mesenchymal stem cells (MSCs), which have stronger proliferation and immunomodulatory ability compared with bone marrow mesenchymal stem cells (BM-MSCs). Besides, as the amniotic membrane is often treated as medical waste after delivery, hAMSCs can be obtained conveniently and noninvasively. The aim of this study was to explore the therapeutic efficacy and underlying mechanisms of hAMSCs transplantation for the humanized aGVHD mouse model. METHODS: We established a humanized aGVHD mouse model by transplanting human peripheral blood mononuclear cells (PBMCs) into NOD-Prkdc(scid)IL2rγ(null) (NPG) mice, human amniotic membrane collected from discarded placenta of healthy pregnant women after delivery and hAMSCs were extracted from amniotic membrane and expanded in vitro. Mice were divided into untreated group (Control), aGVHD group (aGVHD), and hAMSCs treatment group (aGVHD+hAMSCs), the hAMSCs labeled with GFP were administered to aGVHD mice to explore the homing ability of hAMSCs. T effector and regulatory T cells (Tregs) levels and cytokines of each group in target organs were detected by flow cytometry and cytometric bead array (CBA), respectively. RESULTS: We successfully established a humanized aGVHD mouse model using NPG mice. The hAMSCs have the ability to inhibit aGVHD in this mouse model through reduced villous blunting and lymphocyte infiltration of the gut while reducing inflammatory edema, tissue destruction and lymphocyte infiltration into the parenchyma of the liver and lung. hAMSCs suppressed CD3+CD4+ T and CD3+CD8+ T cell expression and increased the proportion of Tregs, and besides, hAMSCs can reduce the levels of IL-17A, INF-γ, and TNF in aGVHD target organs. CONCLUSION: The NPG murine environment was capable of activating human T cells to produce aGVHD pathology to mimic aGVHD as in humans. The hAMSCs controlled aGVHD by decreasing inflammatory cytokine secretion within target organs by modulating the balance of Tregs and T effector cells in humanized mice. Dove 2021-08-16 /pmc/articles/PMC8378934/ /pubmed/34429630 http://dx.doi.org/10.2147/JIR.S323054 Text en © 2021 Gao et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gao, Ya Li, Weiru Bu, Xiaoyin Xu, Ying Cai, Shengchun Zhong, Jinman Du, Meixue Sun, Haitao Huang, Liping He, Yongjian Hu, Xiumei Liu, Qifa Jin, Hua Wang, Qian Ping, Baohong Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title | Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title_full | Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title_fullStr | Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title_full_unstemmed | Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title_short | Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells |
title_sort | human amniotic mesenchymal stem cells inhibit agvhd by regulating balance of treg and t effector cells |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378934/ https://www.ncbi.nlm.nih.gov/pubmed/34429630 http://dx.doi.org/10.2147/JIR.S323054 |
work_keys_str_mv | AT gaoya humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT liweiru humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT buxiaoyin humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT xuying humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT caishengchun humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT zhongjinman humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT dumeixue humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT sunhaitao humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT huangliping humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT heyongjian humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT huxiumei humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT liuqifa humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT jinhua humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT wangqian humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells AT pingbaohong humanamnioticmesenchymalstemcellsinhibitagvhdbyregulatingbalanceoftregandteffectorcells |